🧬 De-Risking Biotech's Biggest Bets | David Li Rerelease (3/4)

🧬 The Biotech Startups Podcast is powered by Excedr: helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network: special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. “You need to be able to project into what will happen when you arrive at the finish line, if and when you arrive at the finish line.” In this part of the podcast, David Li, CEO and co-founder of Meliora Therapeutics, reflects on his experience helping build Everest Detection around the challenge of finding lung cancer earlier. He discusses the potential of a noninvasive, blood-based test, why lung cancer can be difficult to detect in blood, and how access to early-stage clinical samples helped the team investigate the problem. David also compares biotech development with software innovation. Instead of releasing a product, gathering customer feedback, and iterating quickly, life science teams have to define a product profile, test core hypotheses, and de-risk the path to a prototype. He explains how parallel experiments, decision trees, and the distinction between one-way and two-way decisions can help teams move with urgency without treating every choice as irreversible. The conversation closes with a look at fundraising and capital allocation in biotech, where time, money, and risk are closely linked. David shares why raising enough capital to run experiments in parallel can accelerate progress, and why knowing when a project will not reach its next value inflection point is one of a founder's most important responsibilities. Key Topics Covered: The case for earlier lung cancer detection Noninvasive blood-based diagnostics Clinical samples and biological signals Life science innovation versus software development Biotech's slower, engineering-led business cadence Balancing urgency with deliberate decision-making Parallel experiments and decision trees One-way and two-way decisions Defining biotech product-market fit De-risking core hypotheses Fundraising and capital allocation Value inflection points and knowing when to stop If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast:Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4YouTube: https://www.youtube.com/@thebiotechstartupspodcastWebsite: https://www.thebiotechstartupspodcast.com/ Find our guest, David Li, at these links:LinkedIn: https://www.linkedin.com/in/david-li-9aa210bWebsite: https://www.melioratherapeutics.com/ Find our host, Jon Chee, at these links:LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr:LinkedIn: https://www.linkedin.com/company/excedr/Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr:Website: https://flow.page/kyojin Resources & Articles:USPSTF Lung Cancer Screening Recommendation: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screeningStemcentrx Acquisition Announcement: https://investors.abbvie.com/news-releases/news-release-details/abbvie-expand-oncology-presence-through-acquisition-stemcentrxAmazon 2016 Letter to Shareholders: https://www.aboutamazon.com/news/company-news/2016-letter-to-shareholdersEverest Detection: https://everestdetection.com/ Companies, Universities, & People Mentioned:Stemcentrx: https://investors.abbvie.com/news-releases/news-release-details/abbvie-expand-oncology-presence-through-acquisition-stemcentrxGoldman Sachs: https://www.goldmansachs.com/KKR: https://www.kkr.com/Benchling: https://www.benchling.com/ Timestamps:00:00 Intro02:31 Why Early Lung-Cancer Detection Matters03:41 The Case for Blood-Based Screening04:18 Clinical Samples and the Lung-Cancer Signal05:22 Life-Science Innovation Versus Software05:40 A Different Business Cadence06:59 Balancing Urgency and Deliberation07:38 Parallel Experiments and Decision Trees08:12 Reducing Serial Work and Burn09:04 One-Way and Two-Way Decisions10:55 Biotech Product-Market Fit11:11 Defining the Right Biotech Product14:57 De-Risking Core Hypotheses17:04 Fundraising and Capital Allocation18:40 Value Inflection Points and Knowing When to Stop19:18 Outro The Biotech Startups Podcast gives you a front-row seat to the business and science of building a biotech. Hosted by Jon Chee, CEO of Excedr, the show features honest conversations with founders, execs, and investors about their work, their companies, and how they got there. From scientific breakthroughs to startup lessons, each episode explores what it really takes to grow a life science company—from pre-seed to IPO.